Amicus’ latest positive update on Pompe drug hints at accelerated approval pitch
In the latest twist for what’s proved to be a year-long market thriller of dramatic ups and downs, Amicus Therapeutics CEO John Crowley today peeled the covers off an updated — and upbeat — look at how their drug ATB200/AT2221 performed in a Phase I/II study of Pompe disease. And he’s hinting that the positive results could pave the way to an accelerated approval — provided regulators are encouraging.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.